Drugmaker Boehringer Ingelheim appoints former AstraZeneca head to top post
In his new assignment, Gagandeep Singh will take charge from July 10and will also join the board of Boehringer Ingelheim India26-06-2023
26-06-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window
This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Equity Shares of the Company will be closed from June 16, 2023 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending June 30, 2023. We request you to please take the same on record.16-06-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated June 6, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.09-06-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.09-06-2023
AstraZeneca announces launch of cancer medication Tremelimumab in UAE
AstraZeneca has announced the launch of its revolutionary cancer medication, IMJUDO (tremelimumab) in the UAE02-06-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Has Received Permission In Form CT-20 To Import For Sale And Distribution Of Tremelimumab (Imjudo) Concentrate For Solution For Infusion 20 Mg/Ml (25 Mg/1.25 Ml And 300 Mg/15 Ml Presentations In Single Dose Vials) Administered Through Intravenous Route From The Central Drugs Standard Control Organisation, Directorate General Of Health Services, Government Of India.
Please find the enclosed document of the Company with reference to the captioned subject for your reference.01-06-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed document of the Company in relation to the captioned subject.01-06-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Dividend Updates
We wish to inform that at the Meeting of the Board of Directors of the Company held on May 30, 2023, the Board has recommended Dividend of Rs. 16/- per equity share of Rs. 2/- each, subject to the approval of Shareholders at the forthcoming Annual General Meeting of the Company. The Dividend, if approved, by the Shareholders, will be credited/dispatched within 30 days from the date of Annual General Meeting of the Company. This is for your kind information and records.30-05-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Corporate Action-Board approves Dividend
The Board of Directors of the Company at its Meeting held today i.e., May 30, 2023, inter alia, recommended Dividend of Rs. 16/- per equity share for the Financial Year 2022-2330-05-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Appointment Of Mrs. Bhavana Agrawal As Chief Financial Officer Of The Company With Effect From October 1, 2023
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.30-05-2023